ArticleCancers2013
Circulating tumor cells in prostate cancer.
Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Clinical applications and future perspectives of circulating tumor cells in solid tumors.Discover oncology · 2026Review
- Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer.International journal of molecular sciences · 2023Review
- Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.American journal of cancer research · 2023Article
- Recognition and sensitive detection of CTCs using a controllable label-free electrochemical cytosensor.Mikrochimica acta · 2020Article
- Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer.Cancers · 2020Article
- AFM-compatible microfluidic platform for affinity-based capture and nanomechanical characterization of circulating tumor cells.Microsystems & nanoengineering · 2020Article
- Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors.Epigenetics insights · 2020Review
- EUS-Guided Portal Venous Sampling of Circulating Tumor Cells.Current gastroenterology reports · 2019Review
- Antibody-modified reduced graphene oxide film for circulating tumor cell detection in early-stage prostate cancer patients.RSC advances · 2019Article
- Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer.Biomicrofluidics · 2019Article
- Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma.Thoracic cancer · 2018Article
- Progress and challenges of sequencing and analyzing circulating tumor cells.Cell biology and toxicology · 2018Review
- A comprehensive study of circulating tumour cells at the moment of prostate cancer diagnosis: biological and clinical implications of EGFR, AR and SNPs.Oncotarget · 2017Article
- Circulating Tumor DNA as Biomarkers for Cancer Detection.Genomics, proteomics & bioinformatics · 2017Review
- Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine.Frontiers in oncology · 2017Review
- The Potential for Circulating Tumor Cells in Pancreatic Cancer Management.Frontiers in physiology · 2017Review
- Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes.Clinical & experimental metastasis · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual patient's tumor. In prostate cancer, CTC enumeration has been extensively studied and validated as a prognostic tool and has received FDA clearance for use in monitoring advanced disease. More recently, CTC analysis has been shifting from enumeration to more sophisticated molecular characterization of captured cells, which serve as a "liquid biopsy" of the tumor, reflecting molecular changes in an individual's malignancy over time. Here we will review the main CTC studies in advanced and localized prostate cancer, highlighting the important gains as well as the challenges posed by various approaches, and their implications for advancing prostate cancer management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.